Relmada Therapeutics (RLMD) Projected to Post Earnings on Tuesday

Relmada Therapeutics (NASDAQ:RLMD) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter.

Relmada Therapeutics Price Performance

Shares of NASDAQ RLMD opened at $0.27 on Tuesday. The company’s 50 day simple moving average is $0.35 and its 200 day simple moving average is $1.82. The firm has a market capitalization of $8.21 million, a P/E ratio of -0.09 and a beta of 0.65. Relmada Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $6.38.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Leerink Partners reissued a “market perform” rating and set a $1.00 price objective (down previously from $10.00) on shares of Relmada Therapeutics in a research report on Wednesday, December 4th. Mizuho restated a “neutral” rating and set a $1.00 target price (down previously from $23.00) on shares of Relmada Therapeutics in a research note on Thursday, December 5th. Finally, Leerink Partnrs cut shares of Relmada Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. According to MarketBeat, Relmada Therapeutics has an average rating of “Hold” and an average price target of $4.25.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.